Company intelligence / Profile preview

MoCA Cognition

Montreal, Quebec, Canadamocacognition.com ↗

Ownership: Private
Employees: ~50
Development stage: Commercial

Overview

MoCA Cognition's core product—the Montreal Cognitive Assessment—has been validated in over 7,000 studies with references in more than 26,000 articles. It demonstrates superior sensitivity for detecting mild cognitive impairment compared to alternatives like the MMSE. The company has commercialized both paper-based and digital versions of the test globally. In 2024 they launched "XpressO by MoCA," a validated self-assessment app for early detection of MCI. Their tools are widely used by clinicians worldwide.

Therapeutic areas: OncologyPsychiatryCardiovascularNeurology
Modalities: Non-pharmacological therapy
Industry: Digital Health Medical Devices

Partnerships

uMotif partnership for clinical trial data capture/ePRO integration

Beyond the preview

Go deeper on MoCA Cognition.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MoCA Cognition.

Explore the full profile